Back

Fluoropyrimidine-induced cardiovascular toxicity – what is new?

19 June 2026 (10:00 - 10:15)
Organised by: Logo
Congress Presentation Part of: Tackling challenging problems with expert answers Management of Cardiovascular Disease in Patients with Cancer Open Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Professor Charlotte Manisty

University College London, London (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
Permissive cardiotoxicity – how low can you go?
Doctor W. Meijers (Rotterdam, NL)
Slides
Presentation thumbnail
Should we rechallenge immune checkpoint inhibitors after myocarditis?
Professor J. Salem (Paris, FR)
Slides
Presentation thumbnail
Clinical case management: tackling challenging problems with expert answers - discussion

Access the full session

Session thumbnail
Tackling challenging problems with expert answers
Video

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Severe cardiotoxicity due to fluoropyrimidines and the rol of the cardio-oncology team
31 August 2025
thumbnail
Congress Presentation
New target for chemotherapy-induced cardiac dysfunction
20 June 2025
thumbnail
Congress Presentation
Cardiotoxicity of BRAF and MEK inhibitors in patients with melanoma: a real-world longitudinal study incorporating contemporary definitions and risk scores
21 May 2023
thumbnail
Webinar
How to organise cardiovascular monitoring during cancer treatment: who, when and how. ESC 2022 Clinical Practice Guidelines - Webinar Series
26 September 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources